Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS

Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS:

Dementia Big
Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

http://ift.tt/2FfZkAy